Your browser doesn't support javascript.
loading
The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis.
Brown, Lisa; Vranjkovic, Oliver; Li, James; Yu, Kunbo; Al Habbab, Talal; Johnson, Holly; Brown, Krystal; Jablonski, Michael R; Dechairo, Bryan.
Afiliación
  • Brown L; Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA.
  • Vranjkovic O; Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA.
  • Li J; Department of MMM Informatics, Myriad Genetics, Mason, OH 45040, USA.
  • Yu K; Department of MMM Informatics, Myriad Genetics, Mason, OH 45040, USA.
  • Al Habbab T; Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA.
  • Johnson H; Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA.
  • Brown K; Department of Clinical Development, Myriad Genetics, Salt Lake City, UT 84108, USA.
  • Jablonski MR; Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA.
  • Dechairo B; Department of Clinical Development, Myriad Genetics, Salt Lake City, UT 84108, USA.
Pharmacogenomics ; 21(8): 559-569, 2020 06.
Article en En | MEDLINE | ID: mdl-32301649
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD). Patients & methods: The pooled mean effect of symptom improvement and pooled relative risk ratio (RR) of response and remission were calculated using a random effect model. Results: Overall, 1556 patients were included from four studies, with outcomes evaluated at week 8 or week 10. Patient outcomes were significantly improved for patients with MDD whose care was guided by the combinatorial pharmacogenomic test results compared with unguided care (symptom improvement Δ = 10.08%, 95% CI: 1.67-18.50; p = 0.019; response RR = 1.40, 95% CI: 1.17-1.67; p < 0.001; remission RR = 1.49, 95% CI: 1.17-1.89; p = 0.001). Conclusion: GeneSight Psychotropic guided care improves outcomes among patients with MDD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Mayor / Pruebas de Farmacogenómica / Antidepresivos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Pharmacogenomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Mayor / Pruebas de Farmacogenómica / Antidepresivos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Pharmacogenomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido